Fortrea (FTRE) Expected to Release Earnings on Thursday

Fortrea (NASDAQ:FTRE) is expected to be announcing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Fortrea to announce earnings of $0.2172 per share and revenue of $671.57 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Fortrea (NASDAQ:FTRE) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.05. The firm had revenue of $678.20 million for the quarter, compared to analysts’ expectations of $647.57 million. On average, analysts expect Fortrea to post $0.86 EPS for the current fiscal year and $1.04 EPS for the next fiscal year.

Fortrea Stock Performance

FTRE stock opened at $24.43 on Wednesday. The company has a fifty day moving average of $19.95 and a 200-day moving average of $15.66. Fortrea has a one year low of $8.55 and a one year high of $24.83.

Insider Activity at Fortrea

In other news, CEO Anshul Thakral sold 99,869 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $19.16, for a total value of $1,913,490.04. Following the completion of the transaction, the chief executive officer owned 316,797 shares in the company, valued at $6,069,830.52. This trade represents a 23.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on FTRE shares. Deutsche Bank Aktiengesellschaft raised shares of Fortrea from a “hold” rating to a “buy” rating and increased their price target for the stock from $20.00 to $25.00 in a report on Thursday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fortrea in a report on Thursday, October 15th. UBS Group boosted their target price on Fortrea from $22.00 to $24.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 20th. Robert W. Baird set a $23.00 target price on Fortrea in a research report on Thursday, July 30th. Finally, TD Cowen increased their target price on Fortrea from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $22.80.

About Fortrea

Fortrea Holdings Inc is a global contract research organization (CRO) that provides services to pharmaceutical, biotechnology and medical device companies. The company helps clients plan, manage and execute clinical development programs, supporting the testing of new medicines and therapies from early-stage research through regulatory approval and post-approval activities.

Its services include Phase I through Phase IV clinical trials, clinical operations, patient recruitment and access, data management, biostatistics, medical monitoring, pharmacovigilance and regulatory support.